ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

GWP GW Pharm.

735.00
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
GW Pharm. LSE:GWP London Ordinary Share GB0030544687 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 735.00 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

GW Pharmaceuticals PLC Holding(s) in Company (2854N)

28/01/2016 8:47am

UK Regulatory


TIDMGWP

RNS Number : 2854N

GW Pharmaceuticals PLC

28 January 2016

 
 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) 
-------------------------------------------------- 
 
 
 
 1. Identity of the issuer or                                           GW PHARMACEUTICALS PLC 
  the underlying issuer 
  of existing shares to which 
  voting rights are 
  attached: (ii) 
---------------------------------------------------------------  ------------------------------------ 
 2 Reason for the notification (please tick the appropriate 
  box or boxes): 
----------------------------------------------------------------------------------------------------- 
 An acquisition or disposal of voting rights                                        X 
------------------------------------------------------------------  --------------------------------- 
 An acquisition or disposal of qualifying financial 
  instruments which may result in the acquisition 
  of shares already issued to which voting rights 
  are attached 
------------------------------------------------------------------  --------------------------------- 
 An acquisition or disposal of instruments with 
  similar economic effect to qualifying financial 
  instruments 
------------------------------------------------------------------  --------------------------------- 
 An event changing the breakdown of voting rights 
------------------------------------------------------------------  --------------------------------- 
 Other (please 
  specify): 
---------------------------------------------------------  -------  --------------------------------- 
 3. Full name of person(s)                                          The Bank of New York Mellon 
  subject to the                                                            Corporation 
  notification obligation: 
  (iii) 
-----------------------------------------------------------  ---------------------------------------- 
 4. Full name of shareholder(s)                                    The Bank of New York Mellon; 
  (if different from 3.):(iv)                                       The Dreyfus Corporation; The 
                                                                  Boston Company Asset Management 
                                                                     LLC; BNY Mellon, National 
                                                                  Association; BNY Mellon Capital 
                                                                           Markets, LLC. 
-----------------------------------------------------------  ---------------------------------------- 
 5. Date of the transaction                                               26 January 2016 
  and date on 
  which the threshold is 
  crossed or 
  reached: (v) 
-----------------------------------------------------------  ---------------------------------------- 
 6. Date on which issuer                                                  27 January 2016 
  notified: 
-----------------------------------------------------------  ---------------------------------------- 
 7. Threshold(s) that is/are                                             Crossing above 5% 
  crossed or 
  reached: (vi, vii) 
-----------------------------------------------------------  ---------------------------------------- 
 
 
 
 8. Notified details: 
------------------------------------------------------------------------------------------------------------------------ 
 A: Voting rights attached to shares (viii, ix) 
------------------------------------------------------------------------------------------------------------------------ 
 Class/type     Situation previous                 Resulting situation after the 
  of             to the triggering                  triggering transaction 
  shares         transaction 
 
  if possible 
  using 
  the ISIN 
  CODE 
-------------  ---------------------------------  ---------------------------------------------------------------------- 
                Number           Number            Number         Number of                    % of voting 
                 of               of                of shares      voting                       rights (x) 
                 Shares           Voting                           rights 
                                  Rights 
-------------  ---------------  ----------------  -------------  ---------------------------  -------------------------- 
                                                   Direct         Direct          Indirect     Direct         Indirect 
                                                                   (xi)            (xii) 
-------------      -----------    ------------    -------------  --------------  -----------  -------------  ----------- 
 Common Stock   11,862           11,862            11,862         11,862          N/A          0.0045%        N/A 
 GB0030544687 
 
 
 ADR            1,076,351         12,916,212        1,165,618     13,987,416       N/A         5.3270%         N/A 
               ---------------  ----------------  -------------  --------------  -----------  -------------  ----------- 
 US36197T1034 
-------------      -----------    ------------      -----------    ------------  -----------      ---------    --------- 
 
 B: Qualifying Financial Instruments 
------------------------------------------------------------------------------------------------------------------------ 
 Resulting situation after the triggering transaction 
------------------------------------------------------------------------------------------------------------------------ 
 Type of            Expiration     Exercise/                        Number of voting               % of voting 
 financial           date           Conversion                       rights that                    rights 
 instrument          (xiii)         Period (xiv)                     may be 
                                                                     acquired if 
                                                                     the 
                                                                     instrument 
                                                                     is 
                                                                     exercised/ 
                                                                     converted. 
-----------------  -------------  -------------------------------  -----------------------------  ---------------------- 
 
 
 C: Financial Instruments with similar economic effect 
  to Qualifying Financial Instruments (xv, xvi) 
------------------------------------------------------------------------------------------------------------------------ 
 Resulting situation after the triggering transaction 
------------------------------------------------------------------------------------------------------------------------ 
 Type of          Exercise       Expiration      Exercise/        Number of voting               % of voting 
 financial         price         date            Conversion        rights instrument              rights (xix, 
 instrument                      (xvii)          period            refers to                      xx) 
                                                 (xviii) 
---------------  -------------  --------------  ---------------  -----------------------------  ------------------------ 
                                                                                                 Nominal        Delta 
---------------  -------------  --------------  ---------------  -----------------------------  -------------  --------- 
 
 
 Total (A+B+C) 
------------------------------------------------------------------------------------------------------------------------ 
 Number of voting rights                             Percentage of voting rights 
--------------------------------------------------  -------------------------------------------------------------------- 
 13,999,278                                          5.33% 
--------------------------------------------------  -------------------------------------------------------------------- 
 
 
 
 9. Chain of controlled undertakings through which the 
  voting rights and/or the 
  financial instruments are effectively held, if applicable: 
  (xxi) 
---------------------------------------------------------------------------- 
 
   The Bank of New York Mellon Corporation is making this 
   disclosure as the ultimate parent company of: The Bank 
   of New York Mellon; The Dreyfus Corporation; The Boston 
   Company Asset Management LLC; BNY Mellon, National Association 
   and BNY Mellon Capital Markets, LLC. 
 
 Proxy Voting: 
---------------------------------------------------------------------------- 
 10. Name of the proxy holder:                                      N/A 
------------------------------------------------------------  -------------- 
 11. Number of voting rights proxy                                  N/A 
  holder will cease 
  to hold: 
------------------------------------------------------------  -------------- 
 12. Date on which proxy holder will                                N/A 
  cease to hold 
  voting rights: 
------------------------------------------------------------  -------------- 
 
 
  13. Additional information:                                       N/A 
------------------------------------------------------------  -------------- 
 14. Contact name:                                             Andrew Weiser 
------------------------------------------------------------  -------------- 
 15. Contact telephone number:                                 516-338-3752 
------------------------------------------------------------  -------------- 
 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLEAPFPALKKEEF

(END) Dow Jones Newswires

January 28, 2016 03:47 ET (08:47 GMT)

1 Year Gw Pharmaceuticals Chart

1 Year Gw Pharmaceuticals Chart

1 Month Gw Pharmaceuticals Chart

1 Month Gw Pharmaceuticals Chart